Loading
Life sciences · Observational Study
ClinicalTrials.gov · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07904468). This is a study registration, not published results. Lead sponsor: Mardin Artuklu University. Recruitment status: NOT_YET_RECRUITING. Study type: OBSERVATIONAL. Enrollment: 70 participants (ESTIMATED). Conditions: Fibromyalgia. Primary outcome measures: Medication Adherence Assessed by MARS-5 in Relation to Pain Severity , Baseline. Brief summary: This study aims to investigate the relationship between everyday cognitive failures and medication adherence in adults with fibromyalgia. Fibromyalgia is a chronic condition associated with widespread pain, fatigue, and cognitive difficulties such as forgetfulness and problems with attention. These difficulties may affect patients' ability to take prescribed medications regularly, but their relationship with medication adherence remains unclear. This single-center, observational, cross-sectional study will include 70 adults aged 18-65 years diagnosed with fibromyalgia who regularly take at least one medication for the condition. Everyday cognitive failures will be assessed using the Cognitive Failures Questionnaire (CFQ), and medication adherence will be assessed using the five-item Medication Adherence Report Scale (MARS-5). Anxiety and depressive symptoms will be evaluated using the Hospital Anxiety and Depression Scale (HADS). Information on pain severity, medications, and daily medication-taking frequency will also be collected. The study will examine whether greater cognitive failures are associated with lower medication adherence and whether this relationship remains after accounting for anxiety, depressive symptoms, number of regularly used medications, and daily medication-taking frequency. All assessments will be completed during a single visit lasting approximately 12-15 minutes. No experimental treatments, additional laboratory tests, or invasive procedures will be performed.